CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Along with consuming a heart-healthy diet, regularly drinking these beverages can support healthy cholesterol levels. Here's ...

The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...